Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
CASE STUDY
A case of drug induced lupus erythematosus after combined treatment with sodium valproate and risperidone
1
1st Pneumonology Department, General Hospital ""G. Papanikolaou"", Exohi, Thessaloniki, Greece
Corresponding author
Evangelia Fouka
1st Pneumonology Department General Hospital G. Papanikolaou Exohi 57100, Thessaloniki, Greece
1st Pneumonology Department General Hospital G. Papanikolaou Exohi 57100, Thessaloniki, Greece
Pneumon 2012;25(4):436-439
KEYWORDS
ABSTRACT
The case is reported of a 24 year-old male who presented with fever, eosinophilic pleural effusion and positive antinuclear antibodies (ANAs) in the pleural fluid and blood after long-term combined therapy with sodium valproate and risperidone. These pharmaceutical agents have been implicated singly in the emergence of the syndrome of drug induced lupus erythematosus (DILE). Remission of the symptoms΄ and improvement in the clinical and laboratory findings after discontinuation of both drugs strongly suggest that their combination was responsible for the appearance of the syndrome in this patient.
REFERENCES (23)
1.
Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55(2):159-166.
2.
Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301(1):99-105.
3.
Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med 2003; 9(4):254-260.
4.
Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108:166-182.
5.
Rubin RL. Autoantibody specificity in drug-induced lupus and neutrophil -mediated metabolism of lupus-inducing drugs. Clin Biochem 1992; 25(3):223-234.
6.
Pelizza L, De Luca P, La Pesa M, Minervino A. Drug-induced syste-matic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed 2006; 77(1):17-19.
7.
Mongey AB, Hess EV; Medscape. Drug insight: autoimmune effects of medications-what’s new? Nat Clin Pract Rheumatol 2008; 4(3):136-144.
8.
Pigakis K, Ferdoutsis M, Meletis G, Patsourakis G, Bachlitzanakis N. Pulmonary toxicity from cardiovascular drugs. Pneumon. 2009; 22(1):75-84.
9.
Lu Q, Wu A, Richardson BC. Demethylation of the same promoter se-quence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174(10):6212-6219.
10.
Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97(12):2866-2871.
11.
Hieronymus T, Grötsch P, Blank N, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000; 43(9):1994-2004.
12.
Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188(2):387-392.
13.
Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest 1997; 99(8):1888-1896.
14.
Tryfon S, Saroglou M, Kazanas K, et al. Sodium valproate as a cause of recurrent transudative pleural effusion: a case report. J Med Case Reports 2009; 3:51.
15.
Kaufman J, O’Shaughnessy IM. Eoshinophilic pleural effusion assosiated with valproic acid administration. South Med J 1995; 88:881-882.
16.
Chiles C, Joost van Watuum P. Pleural fluid eoshinophilia with combined pharmacotherapy. Psychosomatics 2003; 44(5):436- 437.
17.
Kravetz JD, Federman DG. Valproic acid-induced eoshinophilic pleural effusion. South Med J 2003, 96(8):803-806.
18.
Sleiman C, Raffy O, Roue C, Mal H. Fatal pulmonary haemorrhage during high dose valproate monotherapy. Chest 2000, 117(2):613.
19.
Asconapé JJ, Manning KR, Lancman ME. Systemic lupus erythematosus associated with use of valproate. Epilepsia 1994; 35(1):162-163.
20.
Bleck TP, Smith MC. Possible induction of systemic lupus erythematosus by valproate. Epilepsia 1990; 31(3):343-345.
21.
Bonnet F, Morlat P, De Witte S, Combe C, Beylot J. Lupus-like syndrome and vasculitis induced by valpromide. J Rheumatol. 2003; 30(1):208-209.
22.
Ananth JV, Minn K. Chlorpromazine-induced systemic lupus erythe-matosus. Can Med Assoc J 1973; 108(6):680.
23.
Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011; 34(5):357-374.
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
